Alzheimer's Disease Clinical Trials

Trials for someone you care about with alzheimer's disease.

Brain & Nervous System

Recruiting Drug Device Behavioral Older adults Healthy volunteers

25 trials

Testing Trontinemab against a placebo for Alzheimer's disease

Explore this study →

There are 2 groups in this study. Group A receives Trontinemab. Group B, the placebo group, receives Placebo.

Sites in Toronto, Kelowna and 3 more cities

Phase 3
2 groups
Sites in Kelowna, Peterborough and 3 more cities
Recruiting

Official title: A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

Alzheimer's Disease · Hoffmann-La Roche

Testing SAR448851 against a placebo for Alzheimer's type dementia

Explore this study →

There are 2 groups in this study. Group A receives SAR448851. Group B, the placebo group, receives Placebo.

Sites in Montreal, Ottawa and 1 more city

Phase 2
2 groups
Sites in Ottawa, Toronto and 1 more city
Recruiting

Official title: A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

Dementia, Alzheimer's Type · Sanofi

Testing EXV-802 against a placebo for agitation associated with Alzheimer's disease dementia

Explore this study →

There are 3 groups in this study. Group A receives EXV-802. Group B, the placebo group, receives Placebo. Group C receives EXV-801.

Sites in North York, Peterborough and 1 more city

Phase 2
3 groups
Sites in Peterborough and Whitby
Recruiting

Official title: Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Agitation Associated With Alzheimer's Disease Dementia · Exciva GmbH

Get them matched to the best-fit trials

Answer a few questions and we'll find the closest matches for alzheimer's disease.

Testing Xanomeline/Trospium Chloride with Xanomeline Enteric against a placebo for alzheimer disease

Explore this study →

There are 2 groups in this study. Group A receives one or more of: Xanomeline/Trospium Chloride Capsule and Xanomeline Enteric Capsule. Group B, the placebo group, receives Placebo.

Sites in London, Toronto and 3 more cities

Phase 3
2 groups
Sites in Hamilton, London and 3 more cities
Recruiting

Official title: A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Alzheimer Disease · Bristol-Myers Squibb

Testing Nabilone against a placebo for alzheimer disease

Explore this study →

There are 2 groups in this study. Group A receives Nabilone. Group B, the placebo group, receives Placebo.

Sites in Toronto, Calgary and 4 more cities

Phase 3
2 groups
Sites in Calgary, Hamilton and 4 more cities
Recruiting

Official title: Nabilone for Agitation Blinded Intervention Trial

Alzheimer Disease · Sunnybrook Health Sciences Centre

Testing KarXT with KarX-EC against a placebo for Alzheimer's disease

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives KarXT and KarX-EC. Group B, the placebo group, receives Placebo.

Sites in Greenfield Park, Halifax and 6 more cities

Phase 3
2 groups
Sites in Kelowna, Richmond and 6 more cities
Recruiting

Official title: A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Alzheimer's Disease · Bristol-Myers Squibb

Testing MK-2214 against a placebo for early Alzheimer's disease

Explore this study →

There are 2 groups in this study. Group A receives MK-2214. Group B, the placebo group, receives Placebo.

Sites in Toronto, Montreal and 1 more city

Phase 2
2 groups
Sites in Ottawa, Toronto and 1 more city
Recruiting

Official title: A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Early Alzheimer's Disease · Merck Sharp & Dohme LLC

Testing ALN-APP against a placebo for early-onset alzheimer disease

Explore this study →

There are 3 groups in this study. Groups A and C receive ALN-APP. Group B, the placebo group, receives Placebo.

Sites in Montreal and Toronto

Phase 1
3 groups
Sites in Montreal and Toronto
Recruiting

Official title: A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

Early-Onset Alzheimer Disease · Alnylam Pharmaceuticals

Testing KarXT with KarX-EC for alzheimer disease

Explore this study →

Everyone in this study receives KarXT and KarX-EC.

Sites in Toronto, Hamilton and 2 more cities

Phase 3
1 group
Sites in Hamilton, London and 2 more cities
Recruiting

Official title: A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Alzheimer Disease · Bristol-Myers Squibb

Testing KarXT against a placebo for psychosis associated with Alzheimer's disease

Explore this study →

There are 2 groups in this study. Group A receives KarXT. Group B, the placebo group, receives Placebo.

Sites in Calgary, Hamilton and 4 more cities

Phase 3
2 groups
Sites in Calgary, Hamilton and 4 more cities
Recruiting

Official title: A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Psychosis Associated With Alzheimer's Disease · Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Testing KarXT for psychosis associated with Alzheimer's disease

Explore this study →

Everyone in this study is in one group and receives KarXT.

Sites in Calgary, Hamilton and 3 more cities

Phase 3
1 group
Sites in Calgary, Hamilton and 3 more cities
Recruiting

Official title: Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Psychosis Associated With Alzheimer's Disease · Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Testing ALN-5288 against a placebo for Alzheimer's disease

Explore this study →

There are 2 groups in this study. Group A receives ALN-5288. Group B, the placebo group, receives Placebo and ALN-5288.

Sites in Toronto, Montreal and 1 more city

Phase 1
2 groups
Sites in Montreal, Ottawa and 1 more city
Recruiting

Official title: A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Alzheimer's Disease · Alnylam Pharmaceuticals

Testing ML-007C-MA against a placebo for psychosis associated with Alzheimer's disease

Explore this study →

There are 2 groups in this study. Group A receives ML-007C-MA. Group B, the placebo group, receives Placebo.

Sites in Brampton, Lévis and 2 more cities

Phase 2
2 groups
Sites in Brampton, London and 2 more cities
Recruiting

Official title: A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

Psychosis Associated With Alzheimer's Disease · MapLight Therapeutics

Testing ARO-MAPT-SC against a placebo for alzheimer disease

Explore this study →

There are 2 groups in this study. Group A receives ARO-MAPT-SC. Group B, the placebo group, receives Placebo.

Sites in East York, Montreal and 1 more city

Phase 1
2 groups
Sites in East York, Toronto and 1 more city
Recruiting

Official title: Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease

Alzheimer Disease · Arrowhead Pharmaceuticals

Comparing Methylphenidate with intermittent theta burst stimulation for alzheimer s disease

Explore this study →

There are 2 groups in this study. Group A receives one or more of: intermittent theta burst stimulation (iTBS) and Methylphenidate (MPH). Group B receives intermittent theta burst stimulation (iTBS).

One site, in Toronto

Phase 2
2 groups
One site, in Toronto
Recruiting

Official title: Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia

Alzheimer s Disease · Sunnybrook Health Sciences Centre

Testing Trontinemab against a placebo for alzheimers disease

Explore this study →

There are 2 groups in this study. Group A receives Trontinemab. Group B, the placebo group, receives Placebo.

Sites in Toronto, Montreal and 3 more cities

Phase 3
2 groups
Sites in Richmond, Toronto and 2 more cities
Recruiting

Official title: A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Alzheimers Disease · Hoffmann-La Roche

Testing Remternetug against a placebo for alzheimers disease

Explore this study →

There are 3 groups in this study. Group A receives Remternetug. Group B, the placebo group, receives Matching Placebo (Remternetug). Group C, the comparison group, receives Remternetug.

Sites in Québec, Toronto and 2 more cities

Phase 2
3 groups
Sites in Vancouver, Toronto and 2 more cities
Recruiting

Official title: A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Alzheimers Disease · Washington University School of Medicine

Testing Remternetug (SC) against a placebo for alzheimers disease

Explore this study →

There are 3 groups in this study. Group A receives Remternetug (SC). Group B, the placebo group, receives Matching Placebo (Remternetug). Group C, the comparison group, receives Remternetug (SC).

Sites in Québec, Toronto and 2 more cities

Phase 2
3 groups
Sites in Vancouver, Toronto and 2 more cities
Recruiting

Official title: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Alzheimers Disease · Washington University School of Medicine

Testing Daridorexant against a placebo for alzheimer disease (AD)

Explore this study →

There are 2 groups in this study. Group A receives Daridorexant 50 mg. Group B, the placebo group, receives Placebo.

One site, in Montreal

Phase 2
2 groups
One site, in Montreal
Recruiting

Official title: Daridorexant for Alzheimer Disease Prevention

Alzheimer Disease (AD) · Douglas Mental Health University Institute

Testing Trontinemab against a placebo for alzheimers disease

Explore this study →

There are 2 groups in this study. Group A receives Trontinemab. Group B, the placebo group, receives Placebo.

Sites in Toronto, Halifax and 5 more cities

Phase 3
2 groups
Sites in Kelowna, Halifax and 5 more cities
Recruiting

Official title: A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Alzheimers Disease · Hoffmann-La Roche

Testing GSK4527226 for Alzheimer's disease

Explore this study →

Everyone in this study is in one group and receives GSK4527226.

Sites in Greenfield Park, Ottawa and 3 more cities

Phase 2
1 group
Sites in Ottawa, Peterborough and 3 more cities
Recruiting

Official title: Open-label Extension Study in Participants With Early Alzheimer's Disease

Alzheimer's Disease · GlaxoSmithKline

Comparing methylphenidate with rTMS for alzheimer disease

Explore this study →

There are 2 groups in this study. Group A receives rTMS and methylphenidate. Group B receives rTMS.

One site, in Toronto

2 groups
One site, in Toronto
Recruiting

Official title: rTMS for Apathy Clinical Trial

Alzheimer Disease · Sunnybrook Health Sciences Centre

Testing KarXT with KarX-EC against a placebo for alzheimer disease

Explore this study →

There are 2 groups in this study. Group A, the placebo group, receives KarXT + KarX-EC Arm Matching Placebo. Group B receives KarXT and KarX-EC.

Sites in Montreal, Toronto and 1 more city

Phase 3
2 groups
Sites in Toronto, Whitby and 1 more city
Recruiting

Official title: A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

Alzheimer Disease · Bristol-Myers Squibb

Testing IGC-AD1-Active against a placebo for alzheimer disease

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives IGC-AD1-Active. Group B, the placebo group, receives IGC-AD1-Placebo.

Sites in Hamilton, Montreal and 2 more cities

Phase 2
2 groups
Sites in Victoria, Hamilton and 2 more cities
Recruiting

Official title: Clinical Trial on Agitation in Alzheimer's Dementia

Alzheimer Disease · IGC Pharma, LLC

Testing CBD for alzheimer disease

Explore this study →

There are 2 groups in this study. Group A receives CBD. Group B receives Placebo.

Sites in Toronto, Calgary and 2 more cities

Phase 2
2 groups
Sites in Calgary, London and 2 more cities
Recruiting

Official title: Cannabidiol Medication Intervention Trial

Alzheimer Disease · Sunnybrook Health Sciences Centre

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Alzheimer's Disease trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.